In the epidemiologic data, it is shown that patients who suffered from von Willebrand disease with VWF activity of about 25%29, had approximately 40–60% fewer arterial thrombotic events, which is why we assumed that decreasing VWF activity to 20% or less is of therapeutic interest. Here, VWF is linked to platelet-type von Willebrand disease.